2015
Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial
Rostaing L, Bunnapradist S, Grinyó J, Ciechanowski K, Denny J, Silva H, Budde K, Group E, Denny J, Kulkarni S, Hricik D, Bresnahan B, Bunnapradist S, El-Sabrout R, Chan L, Ciancio G, El-Ghoroury M, Goldstein M, Gaston R, Gohh R, Killackey M, King A, Knight R, Kore A, Sudan D, Friedmann J, Mulgaonkar S, Nolan C, Pankewycz O, Pirsch J, Schaefer H, Steinberg S, Gelb B, True K, West-Thielke P, Waybill M, Wolf J, Ketel B, Harland R, Shihab F, Cassuto E, Le Meur Y, Rostaing L, Mariat C, Grinyó J, Puig J, Seron D, Tisone G, Ciechanowski K, Foroncewicz B, Wlodarczyk Z, Budde K, Witzke O, Mondragon G, Urrea E, Gomez J, Acevedo R, del Carmen Rial M, Novoa P, Silva H, Garcia V, Carvalho D, Saber L, Contieri F, Bastos M, Manfro R, Kanellis J, Eris J, O’Connell P, Hughes P, Russ G, Pidgeon G, Dittmer I, Kee T, Vathsala A, Naumovic R, Mitic I, Parmjeet R. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. American Journal Of Kidney Diseases 2015, 67: 648-659. PMID: 26717860, DOI: 10.1053/j.ajkd.2015.10.024.Peer-Reviewed Original ResearchConceptsTotal daily doseDe novo kidney transplant recipientsNovo kidney transplant recipientsKidney transplant recipientsIR-TacKidney transplantationTransplant recipientsAdverse eventsTreatment failureDaily extended-release tacrolimusDe novo kidney transplantationMean total daily doseLower total daily doseExtended-release tacrolimusOnce-Daily ExtendedTarget trough rangesTwice-Daily TacrolimusNew-onset diabetesSafety end pointSerious adverse eventsPhase 3 trialImmediate-release tacrolimusParticipant eligibility criteriaTwo-year resultsImproved bioavailabilityDuration of Prophylaxis against Fungal Infection in Kidney Transplant Recipients
Guerra CM, Formica RN, Kulkarni S, Asch WS, Tichy EM. Duration of Prophylaxis against Fungal Infection in Kidney Transplant Recipients. Progress In Transplantation 2015, 25: 311-315. PMID: 26645924, DOI: 10.7182/pit2015929.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsTransplant recipientsDuration of admissionCandida esophagitisFungal infectionsAdult kidney transplant recipientsEpisodes of thrushDuration of prophylaxisRetrospective chart reviewPrimary outcome measureFisher's exact testAdministration of nystatinStudent's t-testChart reviewOutcome measuresExact testEsophagitisProphylaxisRecipientsInfectionProtocol changesT-testAdmissionTransplantP-value
2012
Complication Arising from a Duplicated Inferior Vena Cava following Laparoscopic Living Donor Nephrectomy: A Case Report
Christakis P, Cimsit B, Kulkarni S. Complication Arising from a Duplicated Inferior Vena Cava following Laparoscopic Living Donor Nephrectomy: A Case Report. Transplantation Proceedings 2012, 44: 1450-1452. PMID: 22664034, DOI: 10.1016/j.transproceed.2011.11.064.Peer-Reviewed Original ResearchConceptsLaparoscopic living-donor nephrectomyLiving Donor NephrectomyDonor nephrectomyInferior vena cavaVena cavaMultiple emergency room visitsLeft gonadal veinEmergency room visitsEasier surgical approachIntraoperative ligationPostoperative courseFunctioning kidneyGonadal veinRenal veinRoom visitsInferior venaLeft kidneyLikely etiologySurgical approachCase reportRenal vasculatureNephrectomyCavaKidneyPatients
2010
Use of model for end‐stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literature
Caldwell C, Werdiger N, Jakab S, Schilsky M, Arvelakis A, Kulkarni S, Emre S. Use of model for end‐stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literature. Liver Transplantation 2010, 16: 818-826. PMID: 20583082, DOI: 10.1002/lt.22077.Peer-Reviewed Original ResearchConceptsEarly liver transplantationHepatic myelopathyLiver transplantationSpastic paraparesisEnd-Stage Liver Disease (MELD) exception pointsEnd-Stage Liver Disease exceptionCases of LTException pointsCorticospinal tract functionFurther hepatic decompensationSetting of cirrhosisSignificant neurological improvementProgressive spastic paraparesisMELD exception pointsHepatic decompensationMELD scoreNeurological improvementFull ambulationNeurological benefitsPortosystemic shuntingHM patientsClinical stageUnited NetworkWheelchair dependencyEarly transplantation